Overview
With a surge in demand for high-quality clinic-ready viral vectors and the increase in cell and gene therapies gaining more popularity, we see a rising need for developers to find ways to accelerate their development process. Standardized plug-and-play manufacturing platforms could revolutionize viral vector production by effectively expediting product development timelines while being flexible enough to account for each products specific requirements.
